AS
ASCLF.US Ascletis Pharma Inc
- Market cap
- USD 654M
- P/E
- -
- P/B
- 1.92x
- ROE
- -56.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is ASCLF.US undervalued?
Graham numberThe Graham number of Ascletis Pharma Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ascletis Pharma Inc fundamental analysis
No fundamental analysis for Ascletis Pharma Inc yet.
Ascletis Pharma Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ascletis Pharma Inc
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC …
Full company profileAscletis Pharma Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ascletis Pharma Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 33.0M | 53.2M | 166M | 173M | 35.0M | 76.9M | 54.1M | 56.6M | 1.28M | 1.98M | - |
| Gross Profit | 33.0M | 53.2M | 154M | 124M | -23.5M | 39.2M | -24.7M | 26.0M | 735K | -16.6M | -34.3M |
| Operating Income | -42.8M | -98.6M | -134M | -36.4M | -217M | -225M | -344M | -300M | -295M | -471M | -1.49B |
| EBITDA | -40.3M | -93.0M | -131M | -73.6M | -182M | -169M | -284M | -126M | -384M | -454M | -1.46B |
| Net Income | -26.8M | -53.9M | -7.26M | -96.0M | -209M | -199M | -315M | -145M | -301M | -351M | -1.28B |
| EPS | -0.02 | -0.05 | -0.01 | -0.09 | -0.20 | -0.18 | -0.29 | -0.13 | -0.30 | -0.36 | -1.23 |
| Balance Sheet | |||||||||||
| Total Assets | 536M | 991M | 3.53B | 3.43B | 3.07B | 2.83B | 2.66B | 2.49B | 2.12B | 2.07B | 2.45B |
| Total Liabilities | 127M | 121M | 100M | 102M | 85.4M | 101M | 117M | 149M | 158M | 130M | 181M |
| Shareholders' Equity | 272M | 597M | 3.43B | 3.32B | 2.98B | 2.73B | 2.54B | 2.34B | 1.97B | 1.94B | 2.27B |
| Cash & Short-term Investments | 425M | 751M | 3.17B | 2.99B | 2.71B | 2.50B | 2.48B | 2.30B | 1.95B | 1.90B | 2.27B |
| Total Debt | - | - | - | 3.81M | 1.59M | 2.75M | 4.24M | 8.42M | 7.63M | 5.16M | 3.74M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -12.5M | -198M | -96.6M | -74.3M | -84.9M | -147M | -142M | -144M | -342M | -329M | -1.17B |
| Capital Expenditure | 44.6M | 35.9M | 15.8M | 28.2M | 39.0M | 7.20M | 14.4M | 19.2M | 2.15M | 1.60M | 4.93M |
| Free Cash Flow | -57.1M | -234M | -112M | -103M | -124M | -154M | -157M | -163M | -344M | -331M | -1.31B |
| Ratios | |||||||||||
| ROE | -9.8% | -9.0% | -0.2% | -2.9% | -7.0% | -7.3% | -12.4% | -6.2% | -15.3% | -18.1% | -56.3% |
| ROA | -5.0% | -5.4% | -0.2% | -2.8% | -6.8% | -7.0% | -11.8% | -5.8% | -14.2% | -17.0% | -52.2% |
| Net Profit Margin | -81.3% | -101.4% | -4.4% | -55.3% | -597.8% | -258.9% | -582.1% | -255.7% | -23,455.7% | -17,745.6% | - |
| Debt to Equity | - | - | - | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Ascletis Pharma Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | USD 57.8M | 0.07 | - |
| 2017 | USD 57.8M | 0.05 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Ascletis Pharma Inc
- Insiders 65.75%
- Institutions 11.88%
- Public & others 22.37%
- Shares outstanding 1.05B
- Free float 211M
Ascletis Pharma Inc company profile
- Company name
- Ascletis Pharma Inc
- Ticker
- ASCLF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 217
- Fiscal year end
- December
- Address
- Dah Sing Financial Centre, Wan Chai, Hong Kong
- Phone
- 86 571 8538 9730
- Website
- ascletis.com
About Ascletis Pharma Inc
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Further, it offers ASC30, for obesity; ASC47 for muscle-preserving weight loss treatment; and ASC39, a potent and amylin-selective oral small molecule amylin receptor agonist. Ascletis Pharma Inc. was founded in 2013 and is based in Wan Chai, Hong Kong.
Ascletis Pharma Inc management
6- Dr. Jinzi Wu Ph.D.Founder, Chairman & CEO · born 1963
- Ms. Hejingdao WuSenior VP of Operations & Executive Director · born 1974
- Dr. Kristjan Sigurdur GudmundssonSenior Consultant & Head of Discovery · born 1968
- Dr. George Zhengzhi HillSenior Consultant & Chief Medical Advisor · born 1950
- Mr. John P. Gargiulo M.B.A.Chief Business Officer · born 1960
- Mr. Ming Fai Chung CPACompany Secretary · born 1979